NASD · Healthcare · Biotechnology · USA
Insmed Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Insmed is a biopharmaceutical company developing therapies across Respiratory, Immunology & Inflammation, and Neuro & Other Rare diseases. The company commercializes ARIKAYCE for nontuberculous mycobacterial lung infections and BRINSUPRI for non-cystic fibrosis bronchiectasis. Its clinical pipeline includes candidates for pulmonary hypertension, fibrosis, hidradenitis suppurativa, muscular dystrophy, and amyotrophic lateral sclerosis.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Insmed Inc stock.
Overvalued: intrinsic value $28.80 per share, market price $112.58, margin of safety -290.9% (as of 2026-10-30).
A 4.2x revenue multiple, discounted for its losses, values the shares at $28.80; the price of $112.58 is 291% above that value.
Leak Score: 37/100 on 9 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
80 more in this industry show a wider margin of safety.
INSM is overvalued (as of the 2026-10-30 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $28.80; the price of $112.58 is 291% above that value.
$28.80 per share (as of the 2026-10-30 close), against a market price of $112.58. That is a margin of safety of -290.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
37 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.